1. |
Vasilev F, Sukhomyasova A, Otomo T. Mucopolysaccharidosis-plus syndrome. Int J Mol Sci, 2020, 21(2): 421. doi: 10.3390/ijms21020421.
|
2. |
Tebani A, Zanoutene-Cheriet L, Adjtoutah Z, et al. Clinical and molecular characterization of patients with mucopolysaccharidosis typeⅠ in an Algerian Series. Int J Mol Sci, 2016, 17 (5): 743. doi: 10.3390/ijms17050743.
|
3. |
Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis typeⅠ. Cochrane Database Syst Rev, 2019, 6(6): Cd009354. doi: 10.1002/14651858.CD009354.pub5.
|
4. |
Giugliani R, Federhen A, Rojas MV, et al. MucopolysaccharidosisⅠ, Ⅱ, andⅥ: brief review and guidelines for treatment. Genet Mol Biol, 2010, 33(4): 589-604.
|
5. |
Cantú-Reyna C, Vazquez-Cantu DL, Cruz-Camino H, et al. Mucopolysaccharidosis type Ⅰ in Mexico: case-based review. Children (Basel). 2023, 10(4): 642. doi: 10.3390/children10040642.
|
6. |
Hulsebos RG, Zeebregts CJ, De Langen ZJ. Perforation of a congenital umbilical hernia in a patient with Hurler’s syndrome. J Pediatr Surg, 2004, 39(9): 1426-1427.
|
7. |
Gurumurthy T, Shailaja S, Kishan S, et al. Management of an anticipated difficult airway in Hurler’s syndrome. J Anaesthesiol Clin Pharmacol, 2014, 30(4): 558-561.
|
8. |
Mishra SR, Shastri M, Ramesh J. Role of rehabilitation in Hurler’s syndrome. J Back Musculoskelet Rehabil, 2017, 30(3): 635-639.
|
9. |
Muenzer J, Wraith JE, Clarke LA, et al. MucopolysaccharidosisⅠ: management and treatment guidelines. Pediatrics, 2009, 123(1): 19-29.
|